186 related articles for article (PubMed ID: 16420567)
1. A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors.
Santagostino E; Mancuso ME; Rocino A; Mancuso G; Scaraggi F; Mannucci PM
J Thromb Haemost; 2006 Feb; 4(2):367-71. PubMed ID: 16420567
[TBL] [Abstract][Full Text] [Related]
2. Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors.
Santagostino E; Morfini M; Rocino A; Baudo F; Scaraggi FA; Gringeri A
Thromb Haemost; 2001 Oct; 86(4):954-8. PubMed ID: 11686352
[TBL] [Abstract][Full Text] [Related]
3. Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trial.
Kavakli K; Makris M; Zulfikar B; Erhardtsen E; Abrams ZS; Kenet G;
Thromb Haemost; 2006 Apr; 95(4):600-5. PubMed ID: 16601828
[TBL] [Abstract][Full Text] [Related]
4. Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison.
Young G; Shafer FE; Rojas P; Seremetis S
Haemophilia; 2008 Mar; 14(2):287-94. PubMed ID: 18081834
[TBL] [Abstract][Full Text] [Related]
5. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors.
Key NS; Aledort LM; Beardsley D; Cooper HA; Davignon G; Ewenstein BM; Gilchrist GS; Gill JC; Glader B; Hoots WK; Kisker CT; Lusher JM; Rosenfield CG; Shapiro AD; Smith H; Taft E
Thromb Haemost; 1998 Dec; 80(6):912-8. PubMed ID: 9869160
[TBL] [Abstract][Full Text] [Related]
6. Acute hemarthroses: the benefits of early versus late treatment with recombinant activated factor VII.
Lusher JM
Blood Coagul Fibrinolysis; 2000 Apr; 11 Suppl 1():S45-9. PubMed ID: 10850564
[TBL] [Abstract][Full Text] [Related]
7. Controlling acute bleeding episodes with recombinant factor VIIa in haemophiliacs with inhibitor: continuous infusion and bolus injection.
Chuansumrit A; Isarangkura P; Angchaisuksiri P; Sriudomporn N; Tanpowpong K; Hathirat P; Jorgensen LN
Haemophilia; 2000 Mar; 6(2):61-5. PubMed ID: 10781189
[TBL] [Abstract][Full Text] [Related]
8. Single-dose (270 microg kg(-1)) recombinant activated factor VII for the treatment and prevention of bleeds in haemophilia A patients with inhibitors: experience from seven European haemophilia centres.
Pan-Petesch B; Laguna P; Mital A; Stanley J; Torchet MF; Salek SZ; Salaj P
Haemophilia; 2009 May; 15(3):760-5. PubMed ID: 19298382
[TBL] [Abstract][Full Text] [Related]
9. Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency.
Scharrer I
Haemophilia; 1999 Jul; 5(4):253-9. PubMed ID: 10469179
[TBL] [Abstract][Full Text] [Related]
10. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry.
Parameswaran R; Shapiro AD; Gill JC; Kessler CM;
Haemophilia; 2005 Mar; 11(2):100-6. PubMed ID: 15810910
[TBL] [Abstract][Full Text] [Related]
11. Safety of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors: overall rFVIIa exposure and intervals following high (>240 μg kg⁻¹) rFVIIa doses across clinical trials and registries.
Shapiro AD; Neufeld EJ; Blanchette V; Salaj P; Gut RZ; Cooper DL
Haemophilia; 2014 Jan; 20(1):e23-31. PubMed ID: 24354484
[TBL] [Abstract][Full Text] [Related]
12. Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors.
Chai-Adisaksopha C; Nevitt SJ; Simpson ML; Janbain M; Konkle BA
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD011441. PubMed ID: 28944952
[TBL] [Abstract][Full Text] [Related]
13. Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa.
Lentz SR; Ehrenforth S; Karim FA; Matsushita T; Weldingh KN; Windyga J; Mahlangu JN;
J Thromb Haemost; 2014 Aug; 12(8):1244-53. PubMed ID: 24931322
[TBL] [Abstract][Full Text] [Related]
14. Assessment of individual dose utilization vs. physician prescribing recommendations for recombinant activated factor VII (rFVIIa) in paediatric and adult patients with congenital haemophilia and alloantibody inhibitors (CHwI): the Dosing Observational Study in Hemophilia (DOSE).
Gruppo RA; Kessler CM; Neufeld EJ; Cooper DL
Haemophilia; 2013 Jul; 19(4):524-32. PubMed ID: 23551918
[TBL] [Abstract][Full Text] [Related]
15. Haemostatic efficacy and safety of bolus and continuous infusion of recombinant factor VIIa are comparable in haemophilia patients with inhibitors undergoing major surgery. Results from an open-label, randomized, multicenter trial.
Pruthi RK; Mathew P; Valentino LA; Sumner MJ; Seremetis S; Hoots WK;
Thromb Haemost; 2007 Oct; 98(4):726-32. PubMed ID: 17938794
[TBL] [Abstract][Full Text] [Related]
16. Effective prophylaxis with daily recombinant factor VIIa (rFVIIa-Novoseven) in a child with high titre inhibitors and a target joint.
Saxon BR; Shanks D; Jory CB; Williams V
Thromb Haemost; 2001 Oct; 86(4):1126-7. PubMed ID: 11686341
[No Abstract] [Full Text] [Related]
17. Exposure and safety of higher doses of recombinant factor VIIa ≥250 μg kg(-1) in individuals with congenital haemophilia complicated by alloantibody inhibitors: the Haemophilia and Thrombosis Research Society Registry experience (2004-2008).
Neufeld EJ; Kessler CM; Gill JC; Wilke CT; Cooper DL;
Haemophilia; 2011 Jul; 17(4):650-6. PubMed ID: 21299750
[TBL] [Abstract][Full Text] [Related]
18. Single-dose recombinant activated factor VII for the treatment of joint bleeds in hemophilia patients with inhibitors.
Shapiro AD
Clin Adv Hematol Oncol; 2008 Aug; 6(8):579-86. PubMed ID: 18820600
[TBL] [Abstract][Full Text] [Related]
19. rFVIIa and obstructive hydronephrosis.
Louie R; Thomas B; Irwin R
Pediatr Blood Cancer; 2008 Feb; 50(2):431. PubMed ID: 17387704
[No Abstract] [Full Text] [Related]
20. Concomitant infusion of low doses of rFVIIa and FEIBA in haemophilia patients with inhibitors.
Martinowitz U; Livnat T; Zivelin A; Kenet G
Haemophilia; 2009 Jul; 15(4):904-10. PubMed ID: 19473416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
